AOD-9604 Research Guide — HGH Fragment for Metabolic Studies

AOD-9604 (CAS: 221231-10-3) is a synthetic 16-amino acid peptide fragment of human growth hormone, engineered to isolate fat-metabolising properties without activating the growth hormone receptor or raising IGF-1 levels. Preclinical research showed significant lipolytic effects in animal models. Six human clinical trials enrolled over 900 participants and confirmed the safety profile. AOD-9604 is closely related to HGH Fragment 176-191, though they differ chemically in important ways.

What is AOD-9604?

AOD-9604 is a synthetic peptide fragment composed of 16 amino acids derived from the C-terminal region of human growth hormone (hGH). Specifically, it consists of the hGH sequence from amino acids 177 to 191, with a stabilising tyrosine residue added at the N-terminus. The name AOD stands for Advanced Obesity Drug — it was developed by Metabolic Pharmaceuticals Ltd. in Australia during the 1990s under the direction of Professor Frank Ng at Monash University.

The engineering goal was specific: isolate the fat-metabolising properties of full-length hGH while avoiding the growth-promoting, IGF-1-elevating, and glucose-disrupting side effects that make full hGH unsuitable for obesity treatment. The result was a research tool that allows study of adipose tissue lipolysis without the endocrine complexity of systemic growth hormone replacement.

AOD-9604 vs HGH Fragment 176-191: Understanding the Difference

These two terms are frequently used interchangeably in online forums, but they refer to chemically distinct compounds. HGH Fragment 176-191 is the natural sequence of amino acids 176 to 191 at the C-terminal end of hGH — 15 amino acids. AOD-9604 adds a tyrosine residue at the N-terminus, making it 16 amino acids total. This modification was engineered to enhance stability and bioavailability.

The practical difference: AOD-9604 is the version that underwent formal clinical trials. HGH Fragment 176-191 has no published human trial data. For precise laboratory documentation and sourcing, the distinction matters.

Mechanism of Action

Beta-3 Adrenergic Receptor Activation

The primary mechanism of AOD-9604 is upregulation of beta-3 adrenergic receptors (beta-3 ARs) on adipocytes. Beta-3 ARs are G protein-coupled receptors expressed predominantly in adipose tissue and brown fat. Activation triggers a signalling cascade that increases intracellular cAMP, which activates hormone-sensitive lipase (HSL) — the enzyme responsible for triglyceride breakdown. This process is lipolysis: the direct stimulation of stored fat breakdown at the cellular level.

The mechanistic evidence comes from a pivotal 2001 study published in Endocrinology (Heffernan et al., PMID: 11713213). Researchers compared AOD-9604's effects in normal obese mice against beta-3 AR knockout mice — animals genetically engineered to lack the receptor. In normal mice, AOD-9604 significantly reduced body weight and fat mass. In knockout mice, these effects were completely absent. This genetic pathway confirmation is more conclusive than downstream effect studies alone.

Acetyl-CoA Carboxylase Inhibition

The secondary mechanism is inhibition of lipogenesis — the creation of new fat from dietary substrates. AOD-9604 inhibits acetyl-CoA carboxylase (ACC) in adipose tissue, the rate-limiting enzyme in fatty acid synthesis. When ACC is inhibited, the body's capacity to create new fat stores is reduced. This means AOD-9604 works on both sides of the fat storage equation: stimulating breakdown while inhibiting synthesis.

What AOD-9604 Does Not Do

• Does not activate the growth hormone receptor (GHR)
• Does not elevate IGF-1 levels — confirmed in all six human clinical trials
• Does not impair insulin sensitivity or glucose tolerance
• Does not stimulate muscle growth or linear bone growth
• No anti-AOD-9604 antibodies detected — no immunogenicity signal

Research Evidence: What the Studies Show

Preclinical Research: Animal Models

Preclinical evidence for AOD-9604 is robust. Studies in obese rodent models consistently showed significant fat mass reduction, increased lipolysis measured directly in adipose tissue, and histologically confirmed reductions in adipocyte cell size. The Heffernan et al. 2001 beta-3 AR knockout study remains the gold standard for pathway validation: it proved the mechanism is real because when the receptor is removed, the compound stops working entirely.

Effects on lipogenesis were confirmed in isolated rat adipose tissue ex vivo, and remarkably, the same effects were observed in isolated human adipose tissue samples (Heffernan et al., 2000). This early human tissue data gave confidence that animal mechanisms would translate to human biology.

Human Clinical Trials: The Complete Safety Record

Six randomised, double-blind, placebo-controlled trials were completed by Metabolic Pharmaceuticals Ltd. between the late 1990s and 2007, enrolling over 900 participants. The definitive safety analysis was published in 2013 by Stier et al. in the Journal of Endocrinology and Metabolism (PMID: 23761285).

Key findings from all trials combined: No significant IGF-1 elevation at any dose or route; no impairment of glucose tolerance or insulin sensitivity; no anti-AOD-9604 antibodies detected (no immunogenicity); adverse event profile indistinguishable from placebo. Tolerability was confirmed at oral doses up to 30 mg/day and intravenous doses up to 400 mcg/kg.

Why Development Was Discontinued

The Phase IIb efficacy trial (METAOD005) tested 300 obese adults over 12 weeks at multiple doses (1-30 mg/day). The 1 mg dose showed modest weight loss (mean 2.6 kg vs 0.8 kg placebo) — statistically significant but clinically modest. Higher doses did not produce greater weight loss than placebo. The longer 24-week extension trial (METAOD006) failed to replicate even this modest signal. Development was discontinued in 2007 because efficacy did not meet commercial thresholds. The safety case was excellent; the efficacy case was not.

Research Applications

The primary research utility of AOD-9604 is as a tool for studying fat metabolism pathways in isolation from the broader endocrine effects of full hGH. Specifically valuable for:

• Beta-3 adrenergic receptor pharmacology in adipocytes and brown fat
• Hormone-sensitive lipase activation and triglyceride hydrolysis mechanisms
• The relationship between lipolysis and lipogenesis as a coupled metabolic system
• Adipocyte signalling differences in obese versus lean animal models
• Fat oxidation kinetics measured by indirect calorimetry

AOD-9604 has also attracted interest from researchers examining joint health following a 2015 rabbit osteoarthritis model (Kwon et al.) showing intra-articular AOD-9604 enhanced cartilage regeneration. This is early-stage hypothesis-generating research — no human cartilage trials have been conducted as of 2026.

Storage and Handling for Research Use

AOD-9604 is supplied as a lyophilised (freeze-dried) powder and follows standard peptide storage protocols. The compound is sensitive to moisture, heat, and repeated freeze-thaw cycles.

Before reconstitution, verify the CAS number (221231-10-3) on the vial matches the Certificate of Analysis. Confirm HPLC purity is 98%+ and mass spectrometry identity verification against the known molecular weight (~1,817 Da). Allow the sealed vial to equilibrate to room temperature before opening to prevent condensation.

UK Legal Status and Compliance

• Not listed under the Misuse of Drugs Act 1971 — possession is not a criminal offence
• Does not hold MHRA Marketing Authorisation — cannot be legally sold for human therapeutic use
• Legal to purchase as a research chemical for laboratory use from suppliers operating within the research-only framework
• Banned by WADA under the S0 category (non-approved substances) — relevant for competitive athletes

Frequently Asked Questions

Summary

AOD-9604 (CAS: 221231-10-3) is a synthetic 16-amino acid HGH fragment engineered to isolate fat-metabolising pathways without activating the growth hormone receptor or raising IGF-1. The compound is one of the few research peptides to have generated substantial human clinical safety data: six trials enrolling 900+ participants confirmed no IGF-1 elevation, no glucose impairment, and no immunogenicity signal.

The mechanism — beta-3 adrenergic receptor upregulation driving lipolysis and ACC inhibition reducing lipogenesis — is well-characterised and mechanistically validated via genetic knockout models. Development as an obesity drug was discontinued in 2007 after Phase IIb trials showed modest efficacy that did not replicate at scale. The compound's primary research utility remains as a tool for studying adipose tissue metabolism in isolation from systemic growth hormone effects. For UK researchers sourcing AOD-9604, verify CAS 221231-10-3 on the batch COA, confirm HPLC purity at 98%+, and check mass spectrometry identity confirmation against the known molecular weight (~1,817 Da).